These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12753275)

  • 1. Calcimimetic agents: review and perspectives.
    Ureña P; Frazão JM
    Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.
    Ureña P
    Artif Organs; 2003 Sep; 27(9):759-64. PubMed ID: 12940896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The calcimimetic agents: perspectives for treatment.
    Frazão JM; Martins P; Coburn JW
    Kidney Int Suppl; 2002 May; (80):149-54. PubMed ID: 11982829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical use of calcimimetics in the treatment of hyperparathyroidisms].
    Urena P
    Med Sci (Paris); 2004 Nov; 20(11):973-8. PubMed ID: 15525492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future role of calcimimetics in end-stage renal disease.
    Goodman WG; Turner SA
    Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-sensing receptor and calcimimetic agents.
    Coburn JW; Elangovan L; Goodman WG; Frazaõ JM
    Kidney Int Suppl; 1999 Dec; 73():S52-8. PubMed ID: 10633465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
    Goodman WG
    Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
    Negri AL; Slatopolsky EA
    Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcimimetic agents and the calcium-sensing receptor.
    Coburn JW; Maung HM
    Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):123-32. PubMed ID: 10757216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Parathyroid gland, calcium receptor and calcimimetics].
    Ureña P
    Nephrologie; 2002; 23(4):151-64. PubMed ID: 12125321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.